Furthermore, some hormone receptor positive/HER2-negative breast cancers that appear clinical low risk by pre-operative staging and are genomic low risk by pre-operative biopsy may still be recommended to have adjuvant chemotherapy depending on the outcome of surgical staging after NET and this possible outcome needs to be discussed with patients at the outset of NET. This evidence concerns the gene ERBB2 and breast cancer.